Fig. 1From: Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery diseaseProportion of SGLT2 inhibitor use by the number of the associated factors. The associated factors are younger age (< 70 years), increased body mass index (≥ 25 kg/m2), and increased hemoglobin A1c levels (≥ 7.0% [52 mmol/mol]). Error bars indicate 95% confidence intervals. SGLT2, sodium-glucose co-transporter 2Back to article page